Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?
Primary Purpose
Cerebral Palsy
Status
Terminated
Phase
Phase 4
Locations
Israel
Study Type
Interventional
Intervention
oral baclofen + placebo
placebo + oral baclofen
Sponsored by
About this trial
This is an interventional supportive care trial for Cerebral Palsy focused on measuring nursing homes, children, ages 1-18 years, spastic quadriplegia
Eligibility Criteria
Inclusion Criteria:
- Cerebral palsy nursing homes children ages 1-18 years spastic quadriplegia
Exclusion Criteria:
- active epilepsy severe truncal hypotonia
Sites / Locations
- Saare Zedek Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
group a
group b
Arm Description
Baclofen followed by Placebo
Placebo followed by Baclofen
Outcomes
Primary Outcome Measures
care and comport questionnaires
Secondary Outcome Measures
Full Information
NCT ID
NCT00752934
First Posted
September 15, 2008
Last Updated
December 27, 2018
Sponsor
Shaare Zedek Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00752934
Brief Title
Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?
Study Type
Interventional
2. Study Status
Record Verification Date
December 2018
Overall Recruitment Status
Terminated
Why Stopped
Lack of funding
Study Start Date
October 2010 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
June 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shaare Zedek Medical Center
4. Oversight
5. Study Description
Brief Summary
Baclofen is a drug that reduces the muscle stiffness. In disabled children that have very stiff muscles, the stiffness and secondary changes in the joints may cause discomfort and pain. In this study we will check if treatment with Baclofen reduces pain in disabled children with stiff muscles.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebral Palsy
Keywords
nursing homes, children, ages 1-18 years, spastic quadriplegia
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
group a
Arm Type
Experimental
Arm Description
Baclofen followed by Placebo
Arm Title
group b
Arm Type
Experimental
Arm Description
Placebo followed by Baclofen
Intervention Type
Drug
Intervention Name(s)
oral baclofen + placebo
Intervention Description
Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.
For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.
For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.
Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur.
Intervention Type
Drug
Intervention Name(s)
placebo + oral baclofen
Intervention Description
Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
Primary Outcome Measure Information:
Title
care and comport questionnaires
Time Frame
28 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Cerebral palsy nursing homes children ages 1-18 years spastic quadriplegia
Exclusion Criteria:
active epilepsy severe truncal hypotonia
Facility Information:
Facility Name
Saare Zedek Medical Center
City
Jerusalem
Country
Israel
12. IPD Sharing Statement
Learn more about this trial
Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?
We'll reach out to this number within 24 hrs